Methods and kit for diagnosing tick borne illnesses
View Patent ↗ELISA, Western Blot, and a peptide-based ELISA were applied to clinical specimens from patients with clinical symptoms of tick borne diseases, including Lyme disease. Peptides from different components of Borrelia during different cycles, including peptides from outer surface protein, leukocyte function associated antigens, immunodominant antigens, variable major proteins, and peptides from decorin-binding proteins of Borrelial subspecies ( B. sensu stricto. B. afzelii, B. garinii ) were used. Antibodies against specific peptides from Babesia and Ehrlichia were also measured.
1. A method for determining the presence or possibility of a Borrelia, Babesia , and Ehrlichia infection in a patient, comprising the steps of:
a) determining a level of antibodies against peptides of infective agents from each of Borrelia, Babesia , and Ehrlichia , wherein said Borrelia peptide has the sequence shown in SEQ ID NO: 7, said Babesia peptide has the sequence shown in SEQ ID NO: 12, and said Ehrlichia peptide has the sequence shown in SEQ ID NO: 15 in a sample from said patient;
b) comparing the level of antibodies determined in step a) with levels of said antibodies from at least one healthy control individual, wherein
(i) control levels of antibodies against Borrelia, Babesia , and Ehrlichia indicate that said patient does not have the presence or possibility of Borrelia, Babesia , and Ehrlichia infection;
(ii) levels of antibodies greater than two standard deviations above control levels against said Borrelia peptide indicate a presence or possibility of an infection with Borrelia;
(iii) greater than two standard deviations above control levels of antibodies against peptides of Babesia indicate a presence or possibility of an infection with Babesia ; and
(iv) greater than two standard deviations above control levels of antibodies against peptides of Ehrlichia , indicate a presence or possibility of an infection with Ehrlichia.
2. The method of claim 1 , wherein the Borrelia is a species selected from the group consisting of Borrelia burgdorferi sensu lato, B. garinii, B. sensu stricto , and B. afzelii.
3. The method of claim 1 , wherein step a) further comprises determining a level of antibodies against Treponema.
4. The method of claim 1 , wherein the antibodies are selected from the group consisting of IgG, IgM, and IgA.
5. The method of claim 1 , wherein the antibody levels are determined using an immunoassay.
6. The method of claim 1 , wherein the antibodies in step a) and b) are measured from blood.
7. A kit for diagnosing exposure to Babesia and Ehrlichia infection in a patient comprising at least one peptide of infective agents from each of Babesia and Ehrlichia , wherein said Babesia peptide has the sequence shown in SEQ ID NO: 12, and said Ehrlichia peptide has the sequence shown in SEQ ID NO: 15.
8. The kit of claim 7 , further comprising a Borrelia peptide having the sequence shown in SEQ ID NO: 7.
9. The kit of claim 7 further comprising standards, negative controls, positive controls, substrate, and an immunoassay selected from the group consisting of ELISA test, dot blot, and multi-peptide ELISA Blot.
10. The kit of claim 7 further comprising a component selected from the group consisting of nitrocellulose paper, plastics or combs, directions for preparation of specimens and serum diluents, wash buffers, and substrate buffers.
11. The method of claim 5 , wherein the immunoassay is selected from the group consisting of an ELISA test, dot blot, and Multi-Peptide ELISA Blot.